{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:18:34Z","timestamp":1790619514129,"version":"4.1.0"},"reference-count":35,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Hyperkalemia is a potentially life-threatening condition that requires prompt intervention to prevent cardiac complications. While insulin and glucose administration remains a cornerstone of treatment, inhaled \u03b22-adrenergic agonists have been proposed as a complementary or alternative strategy, particularly in emergency settings. This scoping review aimed to describe the utility of inhaled \u03b22-agonists in lowering serum potassium levels in adult patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A scoping review was conducted following the PRISMA-ScR guidelines and the Joanna Briggs Institute methodology. Experimental studies published within the past ten years evaluating the use of inhaled \u03b22-agonists in adult patients with hyperkalemia were included. Five studies were analyzed (three randomized controlled trials and three quasi-experimental studies), assessing dosage, route of administration, magnitude of potassium reduction, and reported adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Most studies used nebulized salbutamol at a dose of 10 mg, with observed reductions in serum potassium ranging from 0.62 to 1.636 mEq\/L, and a peak effect between 1 and 4 hours post-administration. One study also reported the use of levalbuterol. The most common adverse effects were tachycardia, dizziness, and mild hyperglycemia, all of which were clinically manageable. Efficacy was demonstrated in both patients with chronic kidney disease and in individuals with normal renal function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Inhaled \u03b22-agonists, particularly nebulized salbutamol, represent an effective and safe therapeutic option for the acute reduction of serum potassium in adults with hyperkalemia. Their rapid onset of action and applicability across various patient profiles make them a valuable tool in emergency settings, especially where immediate access to advanced therapies such as dialysis is limited. Further research is warranted to evaluate long-term outcomes, safety in patients with cardiovascular comorbidities, and optimal dosing strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0342309","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T18:26:44Z","timestamp":1770143204000},"page":"e0342309","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Utility of inhaled \u03b22-agonists in reducing serum potassium levels in adult patients with hyperkalemia: A scoping review"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7093-6221","authenticated-orcid":true,"given":"Leonardo","family":"Arzayus-Pati\u00f1o","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley Y.","family":"Hinojosa-Angulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen A.","family":"Rodr\u00edguez-Angulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"S\u00e1nchez-Caicedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Benavides-C\u00f3rdoba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"pone.0342309.ref001","first-page":"1","article-title":"Chronic hyperkalemia, diagnosis and management. Colombian consensus","volume":"93","author":"J Rico-Fontalvo","year":"2023","journal-title":"Arch Cardiol Mex"},{"key":"pone.0342309.ref002"},{"key":"pone.0342309.ref003","volume-title":"Hyperkalemia","author":"LV Simon","year":"2025"},{"key":"pone.0342309.ref004","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ajem.2021.11.030","article-title":"Dispelling myths and misconceptions about the treatment of acute hyperkalemia","volume":"52","author":"AA Gupta","year":"2022","journal-title":"Am J Emerg Med"},{"issue":"3","key":"pone.0342309.ref005","article-title":"Hiperkalemia: art\u00edculo de revisi\u00f3n","volume":"6","author":"S Irizar-Santana","year":"2023","journal-title":"Revista M\u00e9dica UAS"},{"issue":"2","key":"pone.0342309.ref006","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3346\/jkms.1997.12.2.111","article-title":"Acute therapy for hyperkalemia with the combined regimen of bicarbonate and beta(2)-adrenergic agonist (salbutamol) in chronic renal failure patients","volume":"12","author":"HJ Kim","year":"1997","journal-title":"J Korean Med Sci"},{"issue":"2","key":"pone.0342309.ref007","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3165\/jjpn.18.101","article-title":"Efficacy of salbutamol inhalation for hyperkalemia","volume":"18","author":"H Souma","year":"2005","journal-title":"Nihon Shoni Jinzobyo Gakkai Zasshi"},{"issue":"2","key":"pone.0342309.ref008","article-title":"Drug Repositioning for COVID-19","volume":"51","author":"V Benavides-Cordoba","year":"2020","journal-title":"Colomb Med (Cali)"},{"issue":"5","key":"pone.0342309.ref009","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/ki.1990.284","article-title":"Albuterol and insulin for treatment of hyperkalemia in hemodialysis patients","volume":"38","author":"M Allon","year":"1990","journal-title":"Kidney Int"},{"issue":"4","key":"pone.0342309.ref010","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1001\/archinte.1987.00370040095017","article-title":"Potassium-lowering effect of albuterol for hyperkalemia in renal failure","volume":"147","author":"J Montoliu","year":"1987","journal-title":"Arch Intern Med"},{"issue":"3","key":"pone.0342309.ref011","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1378\/chest.115.3.617","article-title":"Salbutamol metered-dose inhaler with spacer for hyperkalemia: how fast? How safe?","volume":"115","author":"A Mandelberg","year":"1999","journal-title":"Chest"},{"key":"pone.0342309.ref012","author":"MJ Rojas Garc\u00eda","year":"2010"},{"key":"pone.0342309.ref013","author":"N Karuna Sree"},{"issue":"6","key":"pone.0342309.ref014","doi-asserted-by":"crossref","first-page":"426","DOI":"10.7326\/0003-4819-110-6-426","article-title":"Nebulized albuterol for acute hyperkalemia in patients on hemodialysis","volume":"110","author":"M Allon","year":"1989","journal-title":"Ann Intern Med"},{"issue":"2","key":"pone.0342309.ref015","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0272-6386(12)80983-8","article-title":"Hypokalemic effects of intravenous infusion or nebulization of salbutamol in patients with chronic renal failure: comparative study","volume":"23","author":"HH Liou","year":"1994","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"pone.0342309.ref016","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.nefro.2023.05.004","article-title":"Documento de consenso sobre el abordaje de la hiperpotasemia","volume":"43","author":"A Ortiz","year":"2023","journal-title":"Nefrolog\u00eda"},{"issue":"2","key":"pone.0342309.ref017","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.pupt.2012.11.003","article-title":"Levalbuterol versus albuterol for acute asthma: a systematic review and meta-analysis","volume":"26","author":"KR Jat","year":"2013","journal-title":"Pulm Pharmacol Ther"},{"issue":"5","key":"pone.0342309.ref018","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s11882-009-0058-6","article-title":"Levalbuterol versus albuterol","volume":"9","author":"BT Ameredes","year":"2009","journal-title":"Curr Allergy Asthma Rep"},{"key":"pone.0342309.ref019","first-page":"1","article-title":"Probiotics and the digestive system. Current evidence","author":"F Mearin","year":"2009","journal-title":"Gastroenterol Hepatol"},{"key":"pone.0342309.ref020","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.2147\/COPD.S252435","article-title":"Nebulized Therapies in COPD: Past, Present, and the Future","volume":"15","author":"IZ Barjaktarevic","year":"2020","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"4","key":"pone.0342309.ref021","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/ppul.24244","article-title":"Salbutamol and ipratropium by inhaler is superior to nebulizer in children with severe acute asthma exacerbation: Randomized clinical trial","volume":"54","author":"R Iramain","year":"2019","journal-title":"Pediatr Pulmonol"},{"issue":"8","key":"pone.0342309.ref022","article-title":"Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD","volume":"2016","author":"WH van Geffen","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"pone.0342309.ref023","author":"Global Initiative for Asthma","year":"2024"},{"key":"pone.0342309.ref024","year":"2024"},{"key":"pone.0342309.ref025","year":"2024"},{"key":"pone.0342309.ref026","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/B0-12-369397-7\/00039-X","article-title":"ATOMIC SPECTROMETRY | Overview","author":"JA Holcombe","year":"2005","journal-title":"Encyclopedia of Analytical Science. Elsevier"},{"issue":"1","key":"pone.0342309.ref027","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0736-4679(03)00133-1","article-title":"Levalbuterol is as effective as racemic albuterol in lowering serum potassium","volume":"25","author":"D Pancu","year":"2003","journal-title":"J Emerg Med"},{"key":"pone.0342309.ref028","author":"MDJ Peters","year":"2017"},{"issue":"6","key":"pone.0342309.ref029","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2500\/108854194778816454","article-title":"The beta-2 adrenergic receptor and its agonists","volume":"15","author":"WK Dolen","year":"1994","journal-title":"Allergy Proc"},{"issue":"4","key":"pone.0342309.ref030","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.3390\/ph3041016","article-title":"Beta-Adrenergic Agonists","volume":"3","author":"G Arisione","year":"2010","journal-title":"Pharmaceutics"},{"issue":"2","key":"pone.0342309.ref031","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/ppul.20263","article-title":"Effect of nebulized albuterol on blood glucose in patients with diabetes mellitus with and without cystic fibrosis","volume":"40","author":"P K\u00f6nig","year":"2005","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"pone.0342309.ref032","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ajem.2018.05.016","article-title":"Hypoglycemia as a complication of intravenous insulin to treat hyperkalemia in the emergency department","volume":"37","author":"NL Scott","year":"2019","journal-title":"Am J Emerg Med"},{"key":"pone.0342309.ref033","article-title":"Beta2-agonists","volume-title":"StatPearls","author":"E Hsu","year":"2025"},{"issue":"5","key":"pone.0342309.ref034","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.ajem.2018.10.024","article-title":"Hyperkalemia in the emergency department: Consider the use of nebulized salbutamol","volume":"37","author":"E Montassier","year":"2019","journal-title":"Am J Emerg Med"},{"issue":"1","key":"pone.0342309.ref035","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11154-016-9384-x","article-title":"Updates in hyperkalemia: Outcomes and therapeutic strategies","volume":"18","author":"CP Kovesdy","year":"2017","journal-title":"Rev Endocr Metab Disord"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0342309","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T18:26:49Z","timestamp":1770143209000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0342309"}},"subtitle":[],"editor":[{"given":"Mogamat-Yazied","family":"Chothia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":35,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0342309","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]}}}